Cannabis company Creso Pharma COPHF’s wholly-owned psychedelics subsidiary Halucenex Life Sciences Inc. shared promising early findings on its ongoing Phase 2 clinical trial assessing the efficacy of psilocybin on treatment-resistant PTSD.
The single-arm, open-lab study tests the efficacy of Halucenex’s synthetic psilocybin aqueous solution, Lucenex, in both 10mg and 25mg formats on severe PTSD symptoms of 20 patients.
The psychedelic is being administered in separate sessions in a microdose and macro dose format.
– Read the entire article at Benzinga.
